Open AccessMeropenem at recommended dose is a potential risk for seizure in hemodialysis patient
Author(s) -
Abdullah Al-Hwiesh,
Amani Alhwiesh,
Ibrahiem Saeed Abdul-Rahman,
Abdulrahman Alharbi,
Dujanah Mousa,
Sami Skiker,
Abdulaser Abdulkhani,
Hesham Beheri,
M. A. A. Radi,
Dalal AlKhaldi,
Azeeza Aldwaihi,
Saad Al-Qahtani
Publication year - 2020
Publication title -
saudi journal of kidney diseases and transplantation/našrat amraḍ wa zira'aẗ al-kulaẗ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 30
eISSN - 2320-3838
pISSN - 1319-2442
DOI - 10.4103/1319-2442.308364
Subject(s) - meropenem , discontinuation , medicine , hemodialysis , dose , clearance , pediatrics , surgery , intensive care medicine , antibiotics , urology , biology , antibiotic resistance , microbiology and biotechnology
Dosage adjustment of meropenem is usually recommended in hemodialysis (HD) patients and about 30% of meropenem is cleared during regular HD sessions. However, most of the published trials excluded patients on regular HD. Little is known about the accurate dosage of meropenem needed to avoid central nervous system toxicity. Herein, we report a 65-year-old Saudi female, a known case of end-stage renal disease on regular HD, who was admitted because of pyelonephritis and started on meropenem in the recommended dose according to cultures and sensitivity. She developed tonic-clonic convulsions after the 7 th dose. Seizures were completely aborted after discontinuation of the offending drug. The recommended dosage of 500 mg daily in HD patients may still be too high particularly in Asian patients owing to their relatively small body mass index.